Neoplasm Recurrence, Local
"Neoplasm Recurrence, Local" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The local recurrence of a neoplasm following treatment. It arises from microscopic cells of the original neoplasm that have escaped therapeutic intervention and later become clinically visible at the original site.
MeSH Number(s)
C04.697.655
C23.550.727.655
Concept/Terms
Neoplasm Recurrence, Local- Neoplasm Recurrence, Local
- Local Neoplasm Recurrences
- Locoregional Neoplasm Recurrence
- Recurrences, Local Neoplasm
- Neoplasm Recurrences, Local
- Recurrence, Local Neoplasm
- Recurrence, Locoregional Neoplasm
- Local Neoplasm Recurrence
- Neoplasm Recurrence, Locoregional
- Locoregional Neoplasm Recurrences
- Neoplasm Recurrences, Locoregional
- Recurrences, Locoregional Neoplasm
Below are MeSH descriptors whose meaning is more general than "Neoplasm Recurrence, Local".
Below are MeSH descriptors whose meaning is more specific than "Neoplasm Recurrence, Local".
This graph shows the total number of publications written about "Neoplasm Recurrence, Local" by people in Harvard Catalyst Profiles by year, and whether "Neoplasm Recurrence, Local" was a major or minor topic of these publication.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1991 | 9 | 31 | 40 |
| 1992 | 13 | 18 | 31 |
| 1993 | 15 | 30 | 45 |
| 1994 | 21 | 26 | 47 |
| 1995 | 15 | 32 | 47 |
| 1996 | 23 | 53 | 76 |
| 1997 | 10 | 44 | 54 |
| 1998 | 15 | 39 | 54 |
| 1999 | 25 | 39 | 64 |
| 2000 | 24 | 60 | 84 |
| 2001 | 24 | 35 | 59 |
| 2002 | 25 | 41 | 66 |
| 2003 | 40 | 44 | 84 |
| 2004 | 41 | 38 | 79 |
| 2005 | 45 | 51 | 96 |
| 2006 | 48 | 56 | 104 |
| 2007 | 56 | 77 | 133 |
| 2008 | 72 | 70 | 142 |
| 2009 | 55 | 67 | 122 |
| 2010 | 83 | 71 | 154 |
| 2011 | 94 | 82 | 176 |
| 2012 | 135 | 75 | 210 |
| 2013 | 157 | 104 | 261 |
| 2014 | 145 | 75 | 220 |
| 2015 | 123 | 96 | 219 |
| 2016 | 133 | 86 | 219 |
| 2017 | 138 | 105 | 243 |
| 2018 | 155 | 107 | 262 |
| 2019 | 139 | 124 | 263 |
| 2020 | 83 | 90 | 173 |
| 2021 | 6 | 15 | 21 |
Below are the most recent publications written about "Neoplasm Recurrence, Local" by people in Profiles.
-
Comprehensive CRISPR-Cas9 screens identify genetic determinants of drug responsiveness in multiple myeloma. Blood Adv. 2021 05 11; 5(9):2391-2402.
-
Obinutuzumab and idelalisib in symptomatic patients with relapsed/refractory Waldenström macroglobulinemia. Blood Adv. 2021 05 11; 5(9):2438-2446.
-
Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer. N Engl J Med. 2021 04 22; 384(16):1529-1541.
-
Weathering the Storm: Managing Older Adults With Breast Cancer Amid COVID-19 and Beyond. J Natl Cancer Inst. 2021 04 06; 113(4):355-359.
-
Effect of Celecoxib vs Placebo Added to Standard Adjuvant Therapy on Disease-Free Survival Among Patients With Stage III Colon Cancer: The CALGB/SWOG 80702 (Alliance) Randomized Clinical Trial. JAMA. 2021 04 06; 325(13):1277-1286.
-
Atypical anti-glomerular basement membrane glomerulonephritis in a patient with metastatic melanoma treated with mitogen-activated protein kinase and immune checkpoint inhibitors: a case report. J Med Case Rep. 2021 Apr 03; 15(1):186.
-
Isatuximab plus pomalidomide and dexamethasone in elderly patients with relapsed/refractory multiple myeloma: ICARIA-MM subgroup analysis. Haematologica. 2021 04 01; 106(4):1182-1187.
-
Clinicopathologic Characteristics of Mesonephric Adenocarcinomas and Mesonephric-like Adenocarcinomas in the Gynecologic Tract: A Multi-institutional Study. Am J Surg Pathol. 2021 04 01; 45(4):498-506.
-
Avelumab plus standard-of-care chemoradiotherapy versus chemoradiotherapy alone in patients with locally advanced squamous cell carcinoma of the head and neck: a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial. Lancet Oncol. 2021 04; 22(4):450-462.
-
Autologous stem cell transplantation after anti-PD-1 therapy for multiply relapsed or refractory Hodgkin lymphoma. Blood Adv. 2021 03 23; 5(6):1648-1659.